Current Hypertension Reviews最新文献

{"title":"Three Generation β-Blockers for Atrial Fibrillation Treatment.","authors":"Arthur C Francisco,&nbsp;Wanessa M C Awata,&nbsp;Thauann S Lima,&nbsp;Simone R Potje,&nbsp;Clare C Prohaska,&nbsp;Carla S Ceron,&nbsp;Gabriel T do Vale","doi":"10.2174/1573402118666220609161044","DOIUrl":"https://doi.org/10.2174/1573402118666220609161044","url":null,"abstract":"<p><p>The efficiency of blood flowing from the heart depends on its electrical properties. Myocardial electrical activity is associated with generating cardiac action potentials in isolated myocardial cells and their coordinated propagation, which are mediated by gap junctions. Atrial fibrillation (AF) is a common cardiac arrhythmia which causes an aggressive disturbance in cardiac electromechanical function. Moreover, AF increases the risk of stroke and mortality and is a major cause of death. The mechanisms underlying AF involve electrophysiological changes in ion channel expression and function. β-blockers may be useful in patients with chronic AF or in preventing postoperative AF in subjects undergoing coronary artery bypass grafting (CABG) or other types of surgery. The reduction in heart rate induced by β1-adrenergic receptor antagonists may be associated with the beneficial effect of this drug class. Second generation beta-blockers may be considered superior to the first generation due to their selectivity to the β1 receptor as well as avoiding pulmonary or metabolic adverse effects. Third generation beta-blockers may be considered a great option for their vasodilation and antioxidant properties. There is also a new β-blocker, named landilol that also results on reduced risk of post operative AF without adverse effects and its use has been increasing in clinical trials.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9664490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Insights on Drug Delivery System in Hypertension: From Bench to Market.","authors":"Gaurav Sharma,&nbsp;Abhishek Sharma","doi":"10.2174/1573402119666230707120846","DOIUrl":"10.2174/1573402119666230707120846","url":null,"abstract":"<p><p>Hypertension is a significant hazardous aspect for several diseases, like cardiovascular disease, kidney failure, and brain disease. Hypertension has become the most lethal condition globally, affecting approximately 1 billion people aged around 30-79 years worldwide. In the year 2022, India was ranked 170th for men and 193rd for women for HTN diagnosis rates among 200 countries worldwide. The main risk factor for cardiac failure and stroke is hypertension. The conventional classes of antihypertensive medications currently available have some side effects. Previously, hypertension has been discussed by various researchers using conventional drug-targeting methods such as ACE inhibitors, aldosterone inhibitors, or renin inhibitors. Recently, novel drug delivery technologies utilizing nanoparticles and new pharmacological classes like ACE2 and APA inhibitors have been studied for the medication of hypertension. In this review, we have covered the epidemiology of hypertension in India, its pathophysiology, medications used in the management of hypertension using nanotechnology, and antihypertensive drugs currently available in the market that are approved and patented. Finally, we have covered how hypertension can be managed with the help of smart devices and artificial intelligence (AI) for improved therapy.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10194890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Accuracy of Gestosis Score in Comparison to multi-marker Screening as a Predictor of Preeclampsia at 11-14 Weeks of Pregnancy: A Cohort Study.","authors":"Priya Khanijo, Ruchira Nautiyal, Mishu Mangla, Rashmi Rajput, Manju Saini","doi":"10.2174/1573402119666230803114504","DOIUrl":"10.2174/1573402119666230803114504","url":null,"abstract":"<p><strong>Background: </strong>Pre-eclampsia is a pregnancy-specific multisystemic disorder associated with adverse feto-maternal outcomes. Low-dose Aspirin therapy started in early pregnancy in high-risk women, has significantly reduced the chances of developing PE. Therefore, screening and identification of at-risk mothers are crucial. The present study was planned to study the predictive ability of gestosis score in predicting early-onset pre-eclampsia by comparing it with the multi-marker model.</p><p><strong>Material and methods: </strong>One hundred sixteen women, more than 19 years of age, with live singleton pregnancy at 11-13 weeks of gestation were recruited from the antenatal outpatient department and formed the study cohort. After a detailed history, screening for pre-eclampsia was performed both by multi-marker screening and by gestosis score. Diagnostic accuracy was compared for the two methods of screening.</p><p><strong>Results: </strong>The incidence of pre-eclampsia in the present study cohort was 26.7%. The sensitivity of gestosis score >/= 3 was 84.38% (67.21-94.72) and specificity was 93.18% (85.75-97.46 %). The positive predictive value was 81.82% (67.2%-90.81%), and the negative predictive value was 94.25 (87.98 - 97.35%). The diagnostic accuracy of the gestosis score was 90.83%.</p><p><strong>Conclusion: </strong>Gestosis scoring is a potential tool that can be used as a cost-effective screening method for pre-eclampsia at 11-14 weeks of gestation in low-resource settings. The sensitivity and negative predictive value of the gestosis score is comparable to multi-marker screening using maternal factors, MAP, Uterine artery PI, PAPP-A, and PlGF.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9927504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review on Pharmacognostic, Phytochemical and Pharmacological Characteristics of Medicinal Plants which can be used to Design a Novel Ayurvedic Formulation to Treat Hypertension in Multidimensional Approaches.","authors":"Rahul Maurya,&nbsp;Thirupataiah Boini,&nbsp;Lakshminarayana Misro,&nbsp;Thulasi Radhakrishnan,&nbsp;Ravindra Singh","doi":"10.2174/1573402119666230221084859","DOIUrl":"10.2174/1573402119666230221084859","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is a cardiovascular disorder that is an incurable clinical condition. It requires lifelong therapy for its management along with long terms application of synthetic drugs associated with severe toxicity in multiple organs. However, the therapeutic application of herbal medicines to treat hypertension has gained considerable attention. The limitations and hurdles associated with conventional plant extract medications are their safety, efficacy, dose, and unknown biological activity.</p><p><strong>Objective: </strong>In the modern era, the active phytoconstituent-based formulation has come into trend. Various extraction techniques have been reported to extract and isolate active phytoconstituents. Pharmacognostic, physiochemical, phytochemical, and quantitative analytical methods were developed for their qualitative and quantitative analysis. The passage of time and changes in lifestyle also modulate the variable cause of hypertension. Single-drug-based approach therapy cannot efficiently control the cause of hypertension. Designing a potent herbal formulation with different active constituents and modes of action against hypertension is necessary to effectively manage hypertension.</p><p><strong>Methods: </strong>This review comprises a selection of three different plants, <i>Boerhavia diffusa, Rauwolfia Serpentina</i>, and <i>Elaeocarpus ganitrus</i> exhibiting antihypertension activity.</p><p><strong>Results: </strong>The objective behind selecting individual plants is their active constituents which have different mechanisms of action for the treatment of hypertension. This review comprises the various extraction methods of the active phytoconstituents and pharmacognostic, physiochemical, phytochemical, and quantitative analysis parameters, respectively. It also lists active phytoconstituents present in plants and the different pharmacological modes of action. Selected plant extracts have different antihypertensive mechanisms. Extract of <i>Boerhavia diffusa</i> consisting of Liriodendron & Syringaresnol mono β-D-Glucosidase exhibit Ca²⁺ channel antagonistic activity; where Reserpine is a phytoconstituent of <i>Rauwolfia serpentina</i>, which depletes catecholamine, Ajmalin shows an antiarrhythmic effect by blocking the sodium channel and the aqueous extract of E. ganitrus seeds reduces mean arterial blood pressure by inhibiting the ACE enzyme.</p><p><strong>Conclusion: </strong>It has been revealed that poly-herbal formulation of respective phytoconstituent can be used as potent antihypertensive medicine to treat hypertension effectively.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10183717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post COVID-19 Lockdown in Ghana: What is the Wellbeing Status of the Young Adults?","authors":"Afrifa Daniel,&nbsp;Asamoah Benjamin,&nbsp;Kwofie Emmanuel Amankrah,&nbsp;Asamoah-Mensah Anthony,&nbsp;Medes Francis Osei,&nbsp;Adedugbe Benjamin Oluwole,&nbsp;Moses Mojisola Kemi,&nbsp;Emikpe Abigael Omowumi,&nbsp;Moses Monday Omoniyi,&nbsp;Emikpe Benjamin Obukowho","doi":"10.2174/1573402119666230106140607","DOIUrl":"https://doi.org/10.2174/1573402119666230106140607","url":null,"abstract":"<p><strong>Introduction: </strong>Although optimal wellbeing of young adults (YA) is a vital asset for productivity and measurable and sustainable development, there is a dearth of information on the wellbeing status of YA, especially after the COVID-19 lockdown in Ghana. The study has established the post-lockdown wellbeing status of YA in the COVID-19 pandemic epicenters of Ghana.</p><p><strong>Methods: </strong>The wellbeing status of 1783 (24.49 ± 4.62 year) Ghanaian YA from Kumasi, Accra, and Kasoa (known epicentres of COVID) was assessed in this cross-sectional study. Body mass index (BMI) was calculated, and physical, social, emotional, spiritual and intellectual states were assessed.</p><p><strong>Results: </strong>More females were found to be overweight (315, 17.7%) and obese (160, 9.0%) compared to males. The majority (714; 40.0%) of the young adults were between the ages 25-30 years and overweight, with a mean BMI of 25.46 ± 4.67 kg/m². Overall, 157 (8.8%) had poor, 755 (42.3%) average, 479 (26.9%) good, while 392 (22.0%) had outstanding wellbeing. Specifically, the average grade was recorded for physical (29.07 ± 6.67), spiritual (29.32 ± 6.80), and intellectual (28.29 ± 6.56), while 'good grade' was obtained for social (32.16 ± 5.13) and emotional (31.54 ± 5.07) dimensions of wellbeing.</p><p><strong>Conclusion: </strong>Average Ghanaian YA in the study were overweight (BMI value) and had average wellbeing, which may suggest the risk of cardiovascular diseases. Educational and physical activity interventions with meticulous dietary control and proper understanding of family history, age and genetic factors will help to improve the wellbeing of Ghanaian YA.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9657100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulatory and Placental Expression of Soluble Fms-like Tyrosine Kinase- 1 and Placental Growth Factor in HIV-infected Preeclampsia.","authors":"Zinhle P Mlambo,&nbsp;Olive P Khaliq,&nbsp;Jagidesa Moodley,&nbsp;Thajasvarie Naicker","doi":"10.2174/1573402119666221130164622","DOIUrl":"https://doi.org/10.2174/1573402119666221130164622","url":null,"abstract":"<p><p>An imbalance between angiogenic and anti-angiogenic factors plays a fundamental role in the pathogenesis of preeclampsia (PE). Studies have shown a dysregulation of sFlt-1 and placental growth factor (PlGF) in PE. However, there are differing reports on the levels of these pro-/antiangiogenic factors in HIV-infected preeclamptic and normotensive pregnancies, possibly due to highly active antiretroviral therapy (HAART) and its immune reconstitution effect. The study aimed to investigate the effect of hypertension and ARVs on circulating and placental pro- and antiangiogenic factors in HIV-infected PE. The level of sFlt-1 expression is elevated in PE compared to normal pregnancies. PlGF was altered by placental dysfunction. Antiretroviral therapy does not impact the angiogenic shift in PE development. The angiogenic imbalance evident in the circulatory system by higher sFlt-1 compared to PlGF levels is replicated in the placenta by reduced expression of PlGF receptors in comparison to sFlt-1 receptors. However, there is a lack of data that explore the relationship between HAART and anti-angiogenic factors in the placenta and the circulation of PE comorbid with HIV infection.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9665852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Fixed-dose Combination Amlodipine/Valsartan in Comparison to Two Drug Combination Nebivolol/Valsartan on 24-Hour Ambulatory Blood Pressure.","authors":"Selvia Mf Hanna,&nbsp;Hoda M Rabea,&nbsp;Mohamed Ea Abdelrahim,&nbsp;Hesham B Mahmoud","doi":"10.2174/1573402119666230330082128","DOIUrl":"10.2174/1573402119666230330082128","url":null,"abstract":"<p><strong>Background: </strong>Nebivolol has a dual mechanism of action, exerting a moderate b- blockade effect and reducing peripheral arterial resistance, as a result, the antihypertensive effect of nebivolol may be higher than that of a potent vasodilator CCB such as amlodipine.</p><p><strong>Aim: </strong>The study evaluated the effect of two nebivolol/valsartan on 24 hour ambulatory blood pressure versus amlodipine/valsartan in grade II or III hypertension patients or having uncontrolled BP despite treatment. Ambulatory blood pressure monitoring is a powerful method to monitor the changes in blood pressure over the 24 hour.</p><p><strong>Materials and methods: </strong>A total of 74 from 90 patients continued the study. Fourty patients received amlodipine 10 mg/valsartan 160 mg (group I), and thirty-four patients received nebivolol 5 mg/ valsartan 160 mg (group II). Peripheral blood pressure readings were measured at randomization at 6 and 12 weeks. Ambulatory blood pressure was measured at randomization and 12 weeks.</p><p><strong>Results: </strong>Both drug combinations showed high efficacy in reducing peripheral and 24 hour ambulatory BP. There was no statistically significant difference between the groups in lowering peripheral systolic and diastolic blood pressure at 6 and 12 weeks. Furthermore, both groups failed to show any significant difference in reducing 24 hour SBP and DBP. Regarding day SBP, the blood pressure dropped by -5.63 ± 14.87 in group I and -6.25 ± 11.59 in group II (p = 0.844). Also, group I reduced the day DBP average by -2.53 ± 9.83 and group II by -3.61 ± 9.78 (p = 0.640). In addition, both drug combinations had no statistically significant difference in lowering night SBP and DBP average.</p><p><strong>Conclusion: </strong>Both treatment groups reached the target ambulatory blood pressure, and there was no statistically significant difference between both groups as a regard reduction in all ambulatory blood pressure readings.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10563553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impaired Fasting Glucose (IFG) Prevalence Among Hypolipidemic Treatment- naïve Patients with Hypertension.","authors":"John A Papadakis,&nbsp;Petros Ioannou,&nbsp;George Vrentzos,&nbsp;Vasiliki Theodorakopoulou,&nbsp;K Papanikolaou,&nbsp;Theodosios D Filippatos","doi":"10.2174/1573402118666220321121421","DOIUrl":"https://doi.org/10.2174/1573402118666220321121421","url":null,"abstract":"<p><strong>Background: </strong>Impaired fasting glucose (IFG) predisposes to the future development of type 2 diabetes mellitus (T2DM) and may also be associated with increased cardiovascular disease (CVD) risk. Hypertension is an established CVD risk factor.</p><p><strong>Objective: </strong>This study aimed to assess the prevalence of IFG and the associated anthropometric and metabolic disturbances in patients with hypertension.</p><p><strong>Methods: </strong>Consecutive hypertensive patients not on any hypolipidemic treatment and without a diagnosis of T2DM were included. IFG was defined as serum glucose ≥100 mg/dl according to the American Diabetes Association criteria.</p><p><strong>Results: </strong>The total sample consisted of 1381 participants; between them, 78 patients were diagnosed to have T2DM and they were excluded from the analyses, leaving a final sample of 1303 hypertensive patients [41.0% men; median age 58 (range: 15-90) years] not on any hypolipidemic treatment and without a diagnosis of T2DM. IFG was identified in 469 patients (36%). IFG was more prevalent in males than in females (42.4% vs. 31.8%, p<0.001). Patients with IFG had greater body mass index (BMI), waist-to-hip ratio, systolic blood pressure, pulse pressure, triglycerides, alanine aminotransferase, gamma-glutamyl transferase, and uric acid serum levels compared with patients with normal serum glucose levels.</p><p><strong>Conclusion: </strong>This study reveals that in a sample of patients with hypertension, one out of three has IFG. This is more prevalent among men. IFG is associated with the presence of a more aggravated anthropometric and biochemical profile, possibly associated with an increased CVD risk.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10612685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Cognitive Impairment by Choice Auditory Reaction Time (ART) and Visual Reaction Time (VRT)s during Acute Mental Stress in Young Hypertensives: A Case Control Study.","authors":"Vitthal Khode,&nbsp;Satish Patil,&nbsp;Girish Babu,&nbsp;Komal Ruikar,&nbsp;Sakshi Patel","doi":"10.2174/1573402117666210511010824","DOIUrl":"https://doi.org/10.2174/1573402117666210511010824","url":null,"abstract":"<p><strong>Background: </strong>Acute stress is known to be associated with both negative and positive influences on cognitive performance. Hypertension is one of the risk factors for lowered cognitive performance. Mental stress testing is easier to administer and can be regulated by the investigator. Mental arithmetic using serial subtraction is the most widely used method to administer stress. Reaction time (RT) is widely used to assess cognitive domains like attention, execution and psychomotor speed. Researchers have shown choice reaction times are delayed in hypertension. It is not known whether acute mental stress improves or deteriorates attention, execution and psychomotor speed in hypertension. We hypothesized in the present study that acute mental stress deteriorates cognitive function in hypertensives without overt cerebrovascular disease or other vascular risk factors.</p><p><strong>Methods: </strong>After getting medical ethical clearance from our institution, this case-control study was carried out over eight months (January 2017 to September 2017). 60 subjects between the age group of 35 to 55 years were included in the study. They were divided into 2 groups. Group 1 consisted of 30 diagnosed cases of hypertension at least two years of duration. Group 2 consisted of 30 sex and age-matched controls. MMSE was performed to assess the cognitive function in these groups. Simple (S) and choice (C) auditory reaction time (ART) and visual reaction time (VRT)s were measured at rest and acute mental stress in these groups to assess cognitive function. Predictive value of VRTC resting and VRTC during acute mental stress among hypertensives for cognitive dysfunction was calculated using the receiver operating characteristic (ROC) curve.</p><p><strong>Results: </strong>There was significant difference ART and VRT, both simple and choice, in hypertensive and nonhypertensive subjects and these reaction times further increased during mental stress (P<0.001). VRTC can be a predictor of cognitive dysfunction in hypertensives and during acute mental stress.</p><p><strong>Conclusion: </strong>A significant difference in cognitive functions in hypertensive and nonhypertensive subjects exists and this further deteriorates with acute mental stress.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38902798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ACEi/ ARB and Deaths of COVID-19 Patients.","authors":"Gulam Navi Azad,&nbsp;Anoop Kumar","doi":"10.2174/1573402118666220407093332","DOIUrl":"https://doi.org/10.2174/1573402118666220407093332","url":null,"abstract":"<p><p>The practice of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEi/ARB) in COVID-19 hypertensive patients is still an open question for clinicians to answer. The present study was conducted to find out the association between the use of ACEI/ARB and the mortality rate of COVID-19 patients. The search was conducted from December 2019 to October 2020 in PubMed to identify relevant published studies. RevMan 5 was used for the analysis of the data. The random-effect model was used to calculate the odds ratio. In total, 07 studies were found to be appropriate, reporting a total of 1,566 subjects. The odds ratio was found to be 0.86 [0.41, 1.81], indicating no association between ACEI/ARB and the mortality rate of COVID- 19 patients. In conclusion, we may suggest continuing the use of ACEi/ARB in COVID-19 patients till further pieces of evidence are generated.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10612689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}